Evaluation of Efficacy and Tolerability of Hizentra®

University of South Florida

Status

Unknown

Conditions

Primary Immunodeficiency Disorders

Treatments

Drug: Hizentra

Study type

Interventional

Funder types

Other

Identifiers

NCT01354587

Hizentra

Details and patient eligibility

About

The purpose of this study is to measure the changes in the Treatment Satisfaction Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects transitioning from subcutaneous Vivaglobin® to Hizentra®.

Full description

This trial will evaluate subjects with Primary Immunodeficiency Disorder (PIDD) who are currently self-infusing Vivaglobin therapy for at least six months prior to changing to Hizentra® therapy. Following screening and enrollment, subjects will continue to self-infuse Vivaglobin® for seven infusions and then be converted to subcutaneous Hizentra® treatment which they will continue for the next 6 months. The study will determine if Hizentra® provides improved subject satisfaction by Treatment Satisfaction Questionnaire for Medication. Diaries related to the local site reactions, the number of infusion sites per subject/per dose, volume of Hizentra® per site, duration of infusions, systemic side effects of the new medication and dose on IgG levels and antibody titers, and local site reactions with Hizentra®.

Enrollment

50 estimated patients

Sex

All

Ages

1 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects currently self-infusing with Vivaglobin® for at least six months prior to enrollment.
Diagnosis of antibody deficiency due to primary immune deficiency disease.
Stable serum IgG levels of > 550 mg/dl while on Vivaglobin® based on two determinations at least 8 weeks apart and obtained within 6 months of entry.
Willing to sign consent and follow study schedule.
1 year to 75 years of age.

Exclusion criteria

Evidence of acute systemic illness or infection at within four weeks of screening or enrollment.
Any serious grade 3 or greater toxicity at screening.
History of bleeding or chronic skin disorders.
Selective IgA deficiency in absence of other antibody deficiencies
History of anaphylactic or severe systemic reaction to Vivaglobin.
Pregnant or breastfeeding females.
Use of systemic pre-medication prior to SCIG.
Protein losing enteropathy or nephritic syndrome.
Any condition that in the opinion of the investigator would interfere with the conduct of the study.
Subject or guardian unwilling to sign consent or adhere to study schedule.